Popular topics to explore
Can GLP-1 drugs change India’s productivity story?
A drug can change more than a patient’s weight. It can change how often someone misses work. A recent Danish study of Ozempic users found that long-term sick leave fell after treatment, while employment itself did not meaningfully increas…
Natco Pharma: USFDA Issues Form 483 With Four Observations
NATCOPHARM has received a Form FDA 483 containing four observations following a USFDA inspection at its Finished Dosage Form (FDF) manufacturing facility in Visakhapatnam, Andhra Pradesh.
The observations were issued by the USFDA at the…
Natco Pharma Targets Double-Digit Domestic Growth; Eyes Agri Export Potential
NATCOPHARM is targeting double-digit growth in its domestic business. In the agri business (Crop Health Sciences), the company plans to tap export market potential over the next few years.
The focus remains on strengthening the base bu…
One Drug Just Wiped Out 44% of Natco Pharma's Revenue. Here's a Concept Worth Knowing.
NATCOPHARM reported Q1 FY27 revenue of ₹735.2 crore, down 44.7% year-on-year. Net profit fell 57% to ₹206.5 crore. The cause: weak sales of lenalidomide, its generic cancer drug, previously a major international revenue driver.
The segme…
Q1 results coming today - keep these on radar 👇
✦ Ashok Leyland ✦ Voltas ✦ Bharat Dynamics ✦ NMDC ✦ Cochin Shipyard ✦ Patanjali Foods ✦ Tube Investments ✦ 3M India ✦ Natco Pharma ✦ Jupiter Wagons Mix of largecaps + midcaps + momentum stocks - expect stock-specific moves today.
Update for investors of APLLTD
APLLTD is currently trading at Rs. 829.25, up by 3.90 points or 0.47% from its previous closing of Rs. 825.35 on the BSE.
The scrip opened at Rs. 834.60 and has touched a high and low of Rs. 837.55 and Rs. 828.80 respectively. So far 166…
20th Jul · SEBI-Registered Analyst
The Central Pivot by Vineet Saxena (SEBI RA) · 20th Jul
🧬 Natco Pharma Gets USFDA Tentative Approval for Olaparib Tablets
Natco Pharma has received USFDA tentative approval for Olaparib Tablets (100 mg & 150 mg), the generic version of AstraZeneca's blockbuster cancer drug Lynparza. The company will manufacture the product, while its marketing partner Alembic…
Top Stock-Specific News
TATATECH : Constant currency revenue grew 4.3% QoQ, with management guiding for strong double-digit organic revenue growth in FY27.
ADANIPOWER : Board to consider fundraising via QIP and other avenues at its meeting on July 22.
KERNEX…
Natco Pharma Secures USFDA Tentative Approval for Generic Version of Blockbuster Cancer Drug
Natco Pharma Ltd. has received tentative approval from the US Food and Drug Administration (USFDA) for its generic Olaparib tablets in 100 mg and 150 mg strengths, the generic version of AstraZeneca’s cancer drug Lynparza. Under the partn…
Natco Pharma Ltd
* NATCOPHARM has received tentative USFDA approval for Olaparib tablets, a generic oncology drug, with Alembic Pharmaceuticals set to distribute the product in the U.S. market.
* The addressable U.S. market is significant, with estimated…
Alembic Pharmaceuticals & NATCO Receive Tentative USFDA Approval for Olaparib Tablets
Alembic Pharmaceuticals, in partnership with NATCO Pharma Limited, has received tentative approval from the USFDA for Olaparib Tablets (100 mg and 150 mg). The product is therapeutically equivalent to AstraZeneca’s reference drug, Lynparza.…
Receives Tentative Approval for Olaparib Tablets - Natco Pharma Ltd
Code BSE: 524816 NSE: NATCOPHARM
NATCO receives Tentative Approval for Olaparib Tablets from the United States Food and Drug Administration (U.S. FDA)
NATCO today received tentative approval from the U.S. FDA for Olaparib, 100 mg, and…
Acquisition of additional 13.25% stake in Adcock Ingram Holdings Proprietary Limited. - Natco Pharma Ltd
Code BSE: 524816 NSE: NATCOPHARM
NATCO first acquired 35.75% in Adcock Ingram through its participation in the Adcock Ingram’s delisting process in 2025 following the announcement of a firm intention offer in July 2025, shareholder app…
8th Jul · SEBI-Registered Analyst
Short Term Investing with M.J Research · 8th Jul
Natco Pharma gets nod to invest up to Rs 1,400 crore in NPSAPL
Natco Pharma has secured approval to make an investment of up to Rs 1,400 crore in Natco Pharma South Africa Proprietary (NPSAPL), wholly owned subsidiary of the company. The Board of Directors of the company at its meeting held on July 08,…
Natco Pharma to raise Adcock Ingram stake to 49% for ₹1,069 crore
NATCOPHARM board approved acquiring 19.6 million shares in Adcock Ingram for ₹1,069 crore to raise its stake to 49% and investing ₹1,400 crore in its South African subsidiary, targeting completion by July 2026.
Please note that the inform…
NATCOPHARM Natco Pharma shares are trading around ₹975 today (7 July 2026)
Natco Pharma shares are trading around ₹975 today (7 July 2026), up nearly 4.7% after posting Q4 FY26 results that showed weaker profits but moderate recovery in recent sessions. The company also announced a management change with the super…
LUPIN
Lupin are likely to remain in focus after the drugmaker announced that it has received tentative approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Enzalutamide Tablets in strengt…
Lupin Limited Latest Updates
LUPIN Sharp Net Profit Surges in Q4 FY26
Lupin Limited reported an 87.7% year-on-year jump in consolidated profit after tax (PAT) to ₹1,468.7 crore for the fourth quarter ended March 31, 2026, up from ₹782.4 crore in Q4 FY25. Total revenue…
WOCKPHARMA
The US Food and Drug Administration (FDA) has approved Wockhardt’s novel antibiotic Zaynich for the treatment of complicated urinary tract infections (cUTIs) in adults caused by designated susceptible microorganisms. Zaynich, a combination…
WATCH OUT FOR WEEKLY TOP LOSERS
Natco Pharma Ltd (NATCOPHARM) - The stock witnessed a severe technical breakdown on Friday, May 29, 2026, plunging 13.60% in a single day to close at ₹1,015.90. This massive drop was triggered right alongside the company's Q4 FY25-26 earnin…
